

Podjane Jittamala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2883652/publications.pdf>

Version: 2024-02-01

30
papers

3,545
citations

361413

20
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

4331
citing authors

#	ARTICLE	IF	CITATIONS
1	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	27.0	1,753
2	Determinants of dihydroartemisinin-piperaquine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 952-961.	9.1	252
3	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 943-951.	9.1	219
4	Spiroindolone KAE609 for Falciparum and Vivax Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 403-410.	27.0	197
5	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	13.7	182
6	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria: an open-label phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 61-69.	9.1	147
7	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. <i>New England Journal of Medicine</i> , 2016, 375, 1152-1160.	27.0	89
8	Pharmacokinetic Interactions between Primaquine and Chloroquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3354-3359.	3.2	78
9	Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 576-583.	9.1	67
10	Predicting the severity of dengue fever in children on admission based on clinical features and laboratory indicators: application of classification tree analysis. <i>BMC Pediatrics</i> , 2018, 18, 109.	1.7	65
11	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. <i>ELife</i> , 2021, 10, .	6.0	53
12	Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006440.	3.0	45
13	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7340-7346.	3.2	42
14	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 505-513.	3.2	41
15	A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009144.	3.0	34
16	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. <i>Communications Biology</i> , 2022, 5, 274.	4.4	33
17	Safety, Pharmacokinetics, and Mosquito Lethal Effects of Ivermectin in Combination With Dihydroartemisinin-Piperaquine and Primaquine in Healthy Adult Thai Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1221-1230.	4.7	30
18	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2752-2766.	2.4	28

#	ARTICLE	IF	CITATIONS
19	Evaluation of the GeneXpert MTB/RIF in patients with presumptive tuberculous meningitis. PLoS ONE, 2018, 13, e0198695.	2.5	27
20	Long-term impact of childhood malaria infection on school performance among school children in a malaria endemic area along the Thai-Myanmar border. Malaria Journal, 2015, 14, 401.	2.3	23
21	Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 1615-1621.	3.2	21
22	Identification of the metabolites of ivermectin in humans. Pharmacology Research and Perspectives, 2021, 9, e00712.	2.4	21
23	Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. Journal of Antimicrobial Chemotherapy, 2018, 73, 3102-3113.	3.0	20
24	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. British Journal of Clinical Pharmacology, 2016, 81, 1103-1112.	2.4	19
25	Challenges arising when seeking broad consent for health research data sharing: a qualitative study of perspectives in Thailand. BMC Medical Ethics, 2018, 19, 86.	2.4	18
26	Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children. PLoS ONE, 2019, 14, e0209204.	2.5	10
27	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
28	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Human Vaccines and Immunotherapeutics, 2020, 16, 33-41.	3.3	9
29	Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy. BMJ Open, 2020, 10, e038123.	1.9	9
30	Evaluation and Acceptability of a Simplified Test of Visual Function at Birth in a Limited-Resource Setting. PLoS ONE, 2016, 11, e0157087.	2.5	1